5.8. diagnosis - clinical staging. 5.8.1. t-staging ct category listed table 4.1 (tnm classification) relies dre findings. imaging parameters biopsy results local staging are, far, part staging (within tnm) eau risk category stratification . 5.8.1.1. ultrasound-based techniques computed tomography transrectal us limited accuracy pca local staging . advanced us-based techniques yet tested large-scale studies. case locally-advanced cancers, abdominopelvic us ct may show rectal bladder invasion dilatation upper collecting systems . 5.8.1.2. magnetic resonance imaging t2-weighted imaging remains useful method local staging mri. pooled data meta-analysis showed sensitivity specificity 0.57 (95% ci: 0.49–0.64) 0.91 (95% ci: 0.88–0.93), 0.58 (95% ci: 0.47–0.68) 0.96 (95% ci: 0.95–0.97), 0.61 (95% ci: 0.54–0.67) 0.88 (95% ci: 0.85–0.91), epe, svi, overall stage t3 assessment, respectively . detection epe svi seems accurate high field strength (3 tesla) , added value functional imaging remains debated . 552 men treated rp seven different dutch centres, mri showed significantly higher sensitivity (51% vs. 12%; p < 0.001), lower specificity (82% vs. 97%; p < 0.001) dre non-organ confined disease. risk groups redefined using mri findings rather dre findings showed better bcr-free survival due improved discrimination roger’s phenomenon . traditionally, epe/svi assessed visually using qualitative signs (e.g., capsular disruption, visible tumour within peri-prostatic fat). inter-reader agreement subjective reading moderate, kappa (k) values ranging 0.41 0.68 . length tumour capsule contact (lcc) also significant predictor epe; advantage quantitative, although ideal cut-off value remains debated . several grading systems combining subjective qualitative signs and/or lcc score shown good sensitivity (0.64–0.82) specificity (0.64-0.93) epe, substantial inter-reader agreement(κ = 0.56–0.74). none scores shown definitive superiority others . magnetic resonance imaging findings improve prediction pathological stage combined clinical biopsy data. result, several groups developed multivariate risk calculators predicting epe/svi positive surgical margins . external validation cohorts, risk calculators showed significantly better discrimination nomograms without mri-based features [388-390]. however, results must interpreted care given potential miscalibration due varying prevalence epe/svi. given low sensitivity focal (microscopic) epe, mri recommended local staging low-risk patients. however, mri still useful treatment planning. 5.8.2. n-staging 5.8.2.1. computed tomography mri abdominal ct t1-t2-weighted mri indirectly assess nodal invasion using ln diameter morphology. however, size non-metastatic lns varies widely may overlap size ln metastases. usually, lns short axis > 8 mm pelvis > 10 mm outside pelvis considered malignant. decreasing thresholds improves sensitivity decreases specificity. result, ideal size threshold remains unclear . computed tomography mri sensitivity less 40% . detection microscopic ln invasion ct < 1% patients isup grade group < 4 cancer, psa < 20 ng/ml, localised disease . diffusion-weighted mri (dw-mri) may detect metastases normal-sized nodes, negative dw-mri cannot rule presence ln metastases, dw-mri provides modest improvement ln staging conventional imaging . 5.8.2.2. risk calculators incorporating mri findings clinical data ct mri lack sensitivity direct detection positive lns, nomograms combining clinical biopsy findings used estimate risk patients harbouring positive lns [397-399]. although nomograms associated good performance, developed using systematic biopsy findings may therefore appropriate patients diagnosed combined mri-targeted biopsy systematic biopsy. two models incorporating mri-targeted biopsy findings mri-derived findings recently underwent external validation . one model tested external cohort 187 patients prevalence ln invasion 13.9% (vs. 16.9% development cohort). c-index 0.73 (vs. 0.81 development cohort); calibration analysis, model tended overpredict actual risk . briganti 2019 model validated external multi-centre cohort 487 patients prevalence 8% ln invasion (vs. 12.5% development cohort). auc 0.79 (vs. 0.81 development cohort). using risk cut-off 7% would avoided ln dissection 273 (56% cohort), missing ln invasion seven patients (2.6% patients 7% threshold; 18% 38 patients ln invasion) . another cohort 150 high-risk patients ln invasion prevalence 26% retrospectively used externally assess four different nomograms. showed high sensitivity (>0.95) low specificity (<0.19) tested thresholds. using 7% threshold, briganti 2019 nomogram sensitivity 0.96 specificity 0.18 . calibration nomogram affected prevalence ln involvement population. 5.8.2.3. choline pet/ct meta-analysis 609 patients, pooled sensitivity specificity choline pet/ct pelvic ln metastases 62% (95% ci: 51–66%) 92% (95% ci: 89–94%), respectively . prospective trial 75 patients intermediate risk nodal involvement (10–35%), sensitivity 8.2% region-based analysis 18.9% patient-based analysis, low clinical value . sensitivity choline pet/ct increases 50% patients high risk 71% patients high risk . 5.8.2.4. prostate-specific membrane antigen-based pet/ct prostate-specific membrane antigen pet/ct uses several different radiopharmaceuticals; published studies used 68ga-labelling psma pet imaging, used 18f-labelling (e.g., 18f-dcfpyl, 18f-psma-1007, 18f-psma-jk-7). psma also attractive target specificity prostate tissue, even expression non-prostatic malignancies benign conditions may cause incidental false-positive findings . multi-centre prospective phase iii imaging trial, investigating men intermediate- high-risk pca underwent rp plnd, showed sensitivity specificity 68ga-psma-11 pet 0.40 (95% ci: 0.34-0.46), 0.95 (95% ci: 0.92-0.97), respectively . line previous results prospective, multi-centre studies addressing accuracy 68ga-psma 18f-dcfpyl pet/ct ln staging patients newly diagnosed pca . comparable results also demonstrated phase ii/iii prospective, multi-centre study (osprey) median specificity 97.9% (95% ci: 94.5–99.4%) median sensitivity 40.3%(28.1–52.5%) pelvic nodal involvement . prostate-specific antigen may predictor positive psma pet/ct. primary staging cohort meta-analysis, however, robust estimates positivity found . comparison psma pet/ct mri performed sr meta-analysis including 13 studies (n = 1,597) . 68ga-psma found higher sensitivity comparable specificity staging pre-operative ln metastases intermediate- high-risk pca . prostate specific membrane antigen pet/ct good sensitivity specificity ln involvement, possibly impacting clinical decision-making. review meta-analysis including 37 articles, subgroup analysis performed patients undergoing psma pet/ct primary staging. per-patient-based analysis, sensitivity specificity 68ga-psma pet 77% 97%, respectively, elnd time rp. per-lesion based analysis, sensitivity specificity 75% 99%, respectively . summary, psma pet/ct sensitive n-staging compared mri, abdominal contrast-enhanced ct choline pet/ct. however, small ln metastases, spatial resolution pet, may still missed. 5.8.2.5. risk calculators incorporating mri psma findings international, multi-centre study incorporated psma pet existing nomograms order predict pelvic ln metastatic disease pca patients. performance three nomograms assessed 757 patients undergoing rarp eplnd. addition psma pet nomograms substantially improved discriminative ability models yielding cross-validated aucs 0.76 (95% ci: 0.70–0.82), 0.77 (95% ci: 0.72–0.83), 0.82 (95% ci: 0.76–0.87), respectively . 5.8.3. m-staging 5.8.3.1. bone scan 99mtc-bone scan highly sensitive conventional imaging technique, evaluating distribution active bone formation skeleton related malignant benign disease. meta-analysis showed combined sensitivity specificity 79% (95% ci: 73–83%) 82% (95% ci: 78–85%) patient level . bone scan diagnostic yield significantly influenced psa level, clinical stage tumour isup grade group . retrospective study investigated association age, psa gs 703 newly diagnosed pca patients referred bone scintigraphy. incidence bone metastases increased substantially rising psa upgrading gs . two studies, dominant gleason pattern 4 found significant predictor positive bone scan . bone scanning performed symptomatic patients, independent psa level, isup grade group clinical stage . 5.8.3.2. fluoride pet/ct, choline pet/ct mri 18f-sodium fluoride (18f-naf) pet pet/ct, similarly bone scintigraphy, assesses presence bone metastases. tracer reported similar specificity superior sensitivity bone scintigraphy detecting bone metastases patients newly diagnosed high-risk pca . interobserver agreement detection bone metastases excellent, demonstrating 18f-naf pet/ct robust tool detection osteoblastic lesions patients pca . remains unclear whether choline pet/ct sensitive bone scan higher specificity fewer indeterminate bone lesions [424-426]. choline pet/ct also advantage detecting visceral nodal metastases. diffusion-weighted whole-body axial skeleton mri sensitive bone scan targeted conventional radiography detecting bone metastases high-risk pca. whole-body mri also detect visceral nodal metastases; shown sensitive specific combined bone scan, targeted radiography abdominopelvic ct . meta-analysis found whole-body mri sensitive choline pet/ct bone scan detecting bone metastases per-patient basis, although choline pet/ct highest specificity . 5.8.3.3. psma pet/ct sr including twelve studies (n = 322) reported high variation 68ga-psma pet/ct sensitivity initial staging (range 33–99%; median sensitivity per-lesion analysis 33–92%, per-patient analysis 66–91%), good specificity (per-lesion 82–100%, per-patient 67–99%), studies demonstrating increased detection rates respect conventional imaging modalities (bone scan ct) . prospective multi-centre study patients high-risk pca curative surgery rt (propsma), 302 patients randomly assigned conventional imaging 68ga-psma-11 pet/ct . primary outcome focused accuracy first-line imaging identification pelvic ln distant metastases. accuracy 68ga-psma pet/ct 27% (95% ci: 23–31) higher ct bone scintigraphy (92% [95% ci: 88–95] vs. 65% [95% ci: 60–69]; p < 0.0001). conventional imaging lower sensitivity (38% [95% ci: 24–52] vs. 85% [95% ci: 74–96]) specificity (91% [95% ci: 85–97] vs. 98% [95% ci: 95–100]) psma pet/ct. furthermore, 68ga-psma pet/ct scan prompted management change frequently compared conventional imaging (41 [28%] men [95% ci: 21–36] vs. 23 [15%] men [95% ci: 10–22], p = 0.08), less equivocal findings (7% [95% ci: 4–13] vs. 23% [95% ci: 17–31]) lower radiation exposure (8.4 msv vs. 19.2 msv; p < 0.001) .the comparison whole body mri psma pet/ct detecting bone metastases led inconclusive opposite results two small cohorts . 5.8.4. summary evidence practical considerations initial n/m staging field non-invasive n- m-staging pca patients evolving rapidly. evidence shows choline pet/ct, psma pet/ct whole-body mri provide sensitive detection ln- bone metastases classical work-up bone scan abdominopelvic ct. view evidence offered randomised, multi-centre propsma trial , replacing bone scan abdominopelvic ct sensitive imaging modalities may consideration patients high-risk pca undergoing initial staging. however, absence prospective studies demonstrating survival benefit, caution must used taking therapeutic decisions . prognosis ideal management patients diagnosed metastatic sensitive tests unknown. particular, unclear whether patients metastases detectable pet/ct whole-body mri managed using systemic therapies only, whether subjected aggressive local metastases-directed therapies . results rcts evaluating management outcome patients (and without) metastases detected choline pet/ct, psma pet/ct mri awaited recommendation made treat patients based results tests. 5.8.5. summary evidence guidelines staging prostate cancer recommendationsstrength ratingany risk group staginguse pre-biopsy magnetic resonance imaging (mri) local staging information.weaklow-risk localised diseasedo use additional imaging staging purposes.strongintermediate-risk diseasefor patients international society urological pathology (isup) grade group 3 disease, include least cross-sectional abdominopelvic imaging bone-scan metastatic screening.weakperform prostate-specific antigen-positron emission tomography/computed tomography (psma-pet/ct) available increase accuracy.weakhigh-risk localised disease/locally advanced diseaseperform metastatic screening using psma-pet/ct available least cross-sectional abdominopelvic imaging bone-scan.strong